DURECT Corporation (DRRX) |
|
6.36 -0.13 (-2%)
|
05-31 11:43 |
|
Open: |
6.5 |
Pre. Close: |
6.49 |
|
High:
|
6.7385 |
Low:
|
6.26 |
|
Volume:
|
21,514 |
Market Cap:
|
156(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 11:16:12 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 8.71 One year: 10.17 |
| Support: |
Support1: 5.35 Support2: 4.05 |
| Resistance: |
Resistance1: 7.46 Resistance2: 8.71 |
| Pivot: |
5.69 |
| Moving Average: |
MA(5): 6.17  MA(20): 5.35
MA(100): 5.22 MA(250): 5.32 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 63 %D(3): 59.9 |
| RSI: |
RSI(14): 64.6 |
| 52-week: |
High: 9.69 Low: 3.17 |
| Average Vol(K): |
3-Month: 119 (K) 10-Days: 163 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DRRX ] has closed below upper band by 24.4%. Bollinger Bands are 49.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.72 - 6.75 |
6.75 - 6.78 |
|
Low:
|
6.03 - 6.06 |
6.06 - 6.09 |
|
Close:
|
6.43 - 6.49 |
6.49 - 6.54 |
|
Company Description |
|
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. |
Headline News |
Mon, 22 May 2023
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur - Yahoo Finance
Sun, 21 May 2023
Tocqueville Asset Management Decreases Stake in DURECT Co ... - Best Stocks
Mon, 08 May 2023
DURECT Corporation Reports First Quarter 2023 Financial Results ... - PR Newswire
Mon, 01 May 2023
DURECT Corporation to Announce First Quarter 2023 Financial ... - PR Newswire
Thu, 27 Apr 2023
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis - Yahoo Finance
Tue, 11 Apr 2023
HC Wainwright & Co. Reiterates DURECT (DRRX) Buy ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
24 (M) |
| Shares Float |
19 (M) |
|
% Held by Insiders
|
1.4 (%) |
|
% Held by Institutions
|
39.5 (%) |
|
Shares Short
|
362 (K) |
|
Shares Short P.Month
|
424 (K) |
Stock Financials |
|
EPS
|
-2.1 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.64 |
|
Profit Margin (%)
|
-187.9 |
|
Operating Margin (%)
|
-184.1 |
|
Return on Assets (ttm)
|
-32.2 |
|
Return on Equity (ttm)
|
-116 |
|
Qtrly Rev. Growth
|
7.3 |
|
Gross Profit (p.s.)
|
0.67 |
|
Sales Per Share
|
0.79 |
|
EBITDA (p.s.)
|
-1.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-3.05 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
9.83 |
|
Price to Sales
|
8.05 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
